Cyclodextrin inclusion complex enhances solubility and antimicrobial activity of chlortetracycline hydrochloride

Chlortetracycline hydrochloride (CTC) is a broad-spectrum tetracycline antibiotic used to prevent or resist different bacterial infections. However, due to its poor aqueous stability and physicochemical instability, its clinical development is limited. To improve such properties, CTC complexation with β-cyclodextrin (β-CD) and 2-hydroxypropanol-β-cyclodextrin (HP-β-CD) was performed using different preparation techniques (Freeze drying and ball milling). Inclusion complexes were comprehensively characterized using different analytical techniques and showed different properties distinct to pure CTC. In the presence of both CDs, CTC solubility was significantly improved. After ratio optimization, the optimal molar ratio after freeze-drying was determined to be 1:5. Compared to pure CTC powder (4 mg/mL), the solubility of CTC/HP-β-CD improved approximately 9 times (36 mg/mL), and a new CTC injection was successfully prepared. The antibacterial activity (in vivo and in vitro) of the CTC/HP-β-CD injection was then examined in natural infection chickens. Pathological tissue images showed that a 20 mg/kg CTC/HP-β-CD dose increased antibacterial activity and therapeutic effects. Additionally, we determined five clinical strains and statistically verified that CTC/HP-β-CD exhibits stronger antibacterial activity compared to CTC and other tetracycline drugs, with the most significant effect observed against Pseudomonas aeruginosa (MIC value of 2 μg/mL). Thus, these findings suggest that CTC/HP-β-CD inclusion complexes could be promising for pharmaceutical development, warranting further clinical evaluation, as solubility was significantly increased, and enhanced antibacterial activity was recorded in vivo and in vitro.